North America Peptide Therapeutics Market

North America Peptide Therapeutics Market Size (2023 to 2028)

The size of the North American peptide therapeutics market is expected to be worth USD 24.11 billion by 2028 from USD 15.22 billion in 2023, growing at a CAGR of 9.64% from 2023 to 2028.

The growing patient population of chronic diseases, particularly cancer majorly drives the peptide therapeutics market growth in the North American region. Approximately 1.9 million new cancer cases were recorded in the U.S. in 2021 alone. Breast and prostate cancer are two specific types that employ peptide-based hormonal therapy, a treatment modality that effectively inhibits the growth of cancer cells within the body. Factors such as obesity elevated alcohol consumption, and estrogen exposure is frequently associated with the development of breast cancer. While several treatment options, including chemotherapy and radiofrequency therapy, are available, the side effects associated with these approaches have prompted cancer patients to seek alternative solutions like peptide therapy. This innovative approach entails the utilization of peptide molecules to bind tumor cells, effectively managing the presence of multiple tumors throughout the body.

Peptide therapies have gained significant traction among individuals struggling with weight issues stemming from hormonal imbalances and from increased consumption of unhealthy foods such as junk food and meat products. Moreover, as obese individuals often resort to surgical interventions to address their weight concerns, the associated risks and potential fatalities have underscored the importance of alternative treatment options. In this context, peptide therapies have emerged as a preferred choice among the obese population due to their ability to promote weight loss effectively. These therapies are available in various forms, including oral pills and injections, providing flexibility and convenience to patients. Furthermore, the pharmaceutical sector and key industry players are actively investing in research and development endeavors to develop novel drug combinations that address a wide range of diseases prevalent in the population. These developments, coupled with the increasing number of product approvals, have further fuelled market demand for peptide therapies.

The growing geriatric population in North America also contributes to the North American peptide therapeutics market growth. With advancing age, individuals face a range of health challenges including arthritis, diabetes, cardiovascular issues and skin problems such as wrinkles. Consequently, there is a rising demand among this demographic for peptide therapies that can address these concerns effectively. Peptide therapy offers several benefits to the aging population, including improved immune system function, reduction of wrinkles, restoration of hormonal balance, enhancement of gut health, and expedited recovery from surgical procedures. As a result, peptide therapies have gained popularity as a viable solution to address the specific health needs of the elderly population.

Side effects associated with the long-time consumption of peptide drugs majorly hamper the market growth in North America. In addition, the high cost of the development of peptide drugs, lack of skilled professionals, poor availability of the drugs in pharmacy stores and lack of awareness among people regarding peptide therapeutics further hinder the market growth in North America.

This research report on the North American peptide therapeutics market has been segmented and sub-segmented into the following categories:

By Type:

• Generic
• Innovative

By Application:

• Metabolic
• Cardiovascular Disorder
• Respiratory
• GIT
• Anti-infection
• Pain
• Dermatology
• CNS
• Renal
• Others

By Type of Manufacturers:

• In-house
• Outsourced

By Route of Administration:

• Parenteral Route
• Oral Route
• Pulmonary
• Mucosal
• Others

By Synthesis Technology:

• Solid Phase Peptide Synthesis (SPPS)
• Liquid Phase Peptide Synthesis (LPPS)
• Hybrid Technology

By Country:

• The United States
• Canada
• Rest of North America

The North American region accounted for the major share of the global market in 2022 and this trend is estimated to continue throughout the forecast period. The widespread adoption of advanced therapies, the presence of robust healthcare infrastructure and increasing healthcare expenditure, growing number of awareness programs by the market participants and non-governmental organizations to promote awareness among people of peptide therapeutics favors the market growth in this region.

The U.S. held the major share of the North American market in 2022 and is expected to continue to lead the market in North America throughout the forecast period owing to the presence of numerous key market participants. The United States has approved a considerable number of peptide drugs, with 60 drugs currently available for the treatment of various diseases. The presence of these manufacturing facilities enables the production of cost-effective peptide drugs, ensuring widespread access to effective treatments across the population. Furthermore, the United States boasts a strong network of clinical trial centers, which further bolsters the market demand for peptide therapies.

Canada captured a notable share of the global market in 2022 and is predicted to witness a healthy CAGR during the forecast period. In Canada, the preference for oral peptide drugs is prominent compared to injections. These drugs are readily available through both online and offline pharmacies, requiring a doctor's prescription for purchase. In the Canadian market, peptide drugs are also utilized for treating infants, particularly for conditions such as childhood lung and kidney diseases.

KEY MARKET PLAYERS:

Eli Lilly and Company, Amgen, Inc., Pfizer, Inc., Bristol-Myers Squibb Company, Ever Neuro Pharma GmbH, Takeda Pharmaceutical Company Limited, AstraZeneca PLC, GlaxoSmithKline plc, Novo Nordisk A/S., Novartis AG, Zealand Pharma AG, AmbioPharm Inc., Bachem Holding AG, PolyPeptide Group, Sanofi SA, Amylin Pharmaceuticals, CirclePharma, Inc., PeptiDream Inc., Apitope Technology, Arch NioPartners, and Galena Biopharmaceuticals are some of the major players in the North American peptide therapeutics market.